Skip to content
value.today

Renibus Therapeutics, Inc.

🇺🇸 Lantana, Texas, USAPharmaceuticalsFounded 2015
Total raised
$180 M
4 rounds on record
Latest round
$111 M
May 2023
First round on record
Feb 2016
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Renibus Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2023$111 MNo. 4$50 to $250 million

Renibus Therapeutics, Inc.: Raise no. 4, May 2023

Investors in this round

59 investors had bought by the notice of Jul 17, 2025: 59 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$111 M of $111 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$148,332
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks finders' fees as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bhupinder Jeffrey Singh · Executive Officer, Director
  • D. Jeffrey Keyser · Executive Officer, Director
  • Jamie Jeffrey Donadio · Executive Officer
  • Carlos Guillem · Director
  • Henrik Jeffrey Rasmussen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Salem Partners LLC (CRD 43363) · Los Angeles, CaliforniaSold in GA, TX

Remarks in the notice

  • On fees: “Issuer paid placement agent cash fee of 1% of aggregate amount of proceeds from sale of Series B Preferred from 06/06/2025 to 06/17/2025 and issued placement agent warrants to purchase up to 96,971 shares of Common Stock (exercise price per share, $1.61).”
  • On the amounts: “Amounts listed include amounts from certain converting SAFEs, which may have been previously reported on Form D, and certain warrants (see Item 15). The SAFEs converted into Series B-1 Preferred Stock at the initial closing of the transaction.”

Signed by D. Jeffrey Keyser, Chief Executive Officer. Newest notice filed Jul 17, 2025 (2 amendments). Read the notice at the SEC.

equity, optionsSEC
Jul 2022$23 MNo. 3$10 to $50 million

Renibus Therapeutics, Inc.: Raise no. 3, Jul 2022

Investors in this round

18 investors had bought by the notice of Aug 22, 2022: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$23 M of $25 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them, other: "Simple Agreement for Future Equity (""SAFE"")"
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$12,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bhupinder Jeffrey Singh · Executive Officer, Director · Chief Medical Officer
  • D. Jeffrey Keyser · Executive Officer, Director · President, Secretary and Chief Operating Officer
  • Frank Jeffrey Stonebanks · Executive Officer, Director · Chief Executive Officer and Chairman of the Board
  • Jamie Jeffrey Donadio · Executive Officer · Chief Financial Officer
  • Carlos Guillem · Director
  • Henrik Jeffrey Rasmussen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Melior Capital Management GMBH · Zug, SwitzerlandSold in no state named, and outside the US

Signed by Frank Stonebanks, Chief Executive Officer and Chairman of the Board. Newest notice filed Aug 22, 2022 (1 amendment). Read the notice at the SEC.

optionsSEC
Sep 2019$35 MNo. 2$10 to $50 million

Renibus Therapeutics, Inc.: Raise no. 2, Sep 2019

Investors in this round

30 investors had bought by the notice of Feb 18, 2022: 30 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$35 M of $35 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$116,640
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • D. Jeffrey Keyser · Executive Officer, Director · President, Secretary and Chief Operating Officer
  • Frank Jeffrey Stonebanks · Executive Officer, Director · Chief Executive Officer
  • Alvaro Guillem · Director · Chairman of the Board
  • Bhupinder Jeffrey Singh · Director
  • Henrik Jeffrey Rasmussen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Melior Capital Management GMBH · Zug, SwitzerlandSold in MA, and outside the US

Remarks in the notice

  • On fees: “In addition, Recipient earned a warrant to purchase equity in the issuer with an initial value equal to 4.0% of the aggregate number of securities issued to investors introduced to issuer by Recipient”

Signed by Frank Stonebanks, Chief Executive Officer. Newest notice filed Feb 18, 2022 (3 amendments). Read the notice at the SEC.

equitySEC
Feb 2016$11 MNo. 1$10 to $50 million

Renibus Therapeutics, Inc.: Raise no. 1, Feb 2016

Investors in this round

112 investors had bought by the notice of May 2, 2016: 112 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$11 M of $13 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carlos Guillem · Executive Officer, Director · Secretary
  • Harpreet Kaur · Executive Officer, Director · Chairman of the Board, Chief Executive Officer and President
  • Nels D. Bergmark · Executive Officer · Treasurer
  • Dale Jones · Director
  • Jennifer D. Rasmussen · Director
  • Jocelyn D. Keyser · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Harpreet Kaur, Chairman of the Board, CEO and President. Newest notice filed May 2, 2016 (3 amendments). Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Renibus Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2025).

    SEC Form D · Jul 2025

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jul 2025

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Renibus Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Renibus Therapeutics, Inc.
NameRoleNamed in
Bhupinder Jeffrey SinghExecutive officerJul 2025
D. Jeffrey KeyserExecutive officerJul 2025
Jamie Jeffrey DonadioExecutive officerJul 2025
Frank Jeffrey StonebanksExecutive officerSep 2023
Alvaro GuillemChairman of the Board, Chief Executive OfficerJul 2020
Carlos GuillemSecretaryMay 2016
Harpreet KaurChairman of the Board, Chief Executive Officer and PresidentMay 2016
Nels D. BergmarkTreasurerMay 2016
Bhupinder Jeffrey SinghDirectorJul 2025
Carlos GuillemDirectorJul 2025
D. Jeffrey KeyserDirectorJul 2025
Henrik Jeffrey RasmussenDirectorJul 2025
Frank Jeffrey StonebanksDirectorSep 2023
Alvaro GuillemChairman of the BoardFeb 2022
Dale JonesDirectorMay 2016
Harpreet KaurChairman of the Board, Chief Executive Officer and PresidentMay 2016
Jennifer D. RasmussenDirectorMay 2016
Jocelyn D. KeyserDirectorMay 2016